Nalaganje...

Targeting Non-Small Cell Lung Cancer Cells by Dual Inhibition of the Insulin Receptor and the Insulin-Like Growth Factor-1 Receptor

Phase III trials of the anti-insulin-like growth factor-1 receptor (IGF1R) antibody figitumumab in non-small cell lung cancer (NSCLC) patients have been discontinued owing to lack of survival benefit. We investigated whether inhibition of the highly homologous insulin receptor (IR) in addition to th...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Vincent, Emma E., Elder, Douglas J. E., Curwen, Jon, Kilgour, Elaine, Hers, Ingeborg, Tavaré, Jeremy M.
Format: Artigo
Jezik:Inglês
Izdano: Public Library of Science 2013
Teme:
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC3691253/
https://ncbi.nlm.nih.gov/pubmed/23826179
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0066963
Oznake: Označite
Brez oznak, prvi označite!